Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi’s Generics Sales Stabilize Post-Zentiva

Emerging Markets Now Account For The Bulk Of Generics Turnover

Executive Summary

Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.

You may also be interested in...

Major Players Swap Positions Among Industry Top 50

The second part of Generics Bulletin’s newly-compiled global sales ranking of generics and biosimilars companies sees a number of major firms sliding up and down the table.

Sanofi Declines Despite Moving Past Zentiva Comparison

After seemingly stabilizing late last year, Sanofi has seen its generics sales once again drop in the first quarter of 2020, despite moving past unfavorable prior-year comparisons with the Zentiva generics business which the company divested in 2018.

Zentiva sets strategy as it starts out alone

Ensuring that Zentiva has the necessary strategy, skills, competencies, capabilities and people to operate independently as a “leading European generics player” is a key priority, the company’s head, Patrick Aghanian, told Generics bulletin as the firm started life as an independent company under the ownership of private-equity investor Advent International.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts